Precision BioSciences to Present at Upcoming June Investor Conferences
05 Junho 2023 - 8:00AM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene
editing company developing ARCUS®-based in vivo gene editing and ex
vivo allogeneic CAR T therapies, today announced that members of
management will participate in the following investor conferences
in June 2023:
Jefferies Global Healthcare Conference 2023 Date: Friday,
June 9, 2023 Time: 10:30 am ET
Goldman Sachs 44th Annual Global Healthcare Conference
Date: Thursday, June 15, 2023 Time: 8:40 am PT (11:40 am ET)
A live webcast of each presentation will be accessible on the
Company’s website www.precisionbiosciences.com, under the Investors
& Media section. An archived replay of the webcasts will be
available for approximately 30 days following each event.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology
company dedicated to improving life (DTIL) with its novel and
proprietary ARCUS® genome editing platform. ARCUS is a highly
precise and versatile genome editing platform that was designed
with therapeutic safety, delivery, and control in mind. Using
ARCUS, the Company’s pipeline consists of several in vivo gene
editing candidates designed to cure genetic and infectious diseases
where no adequate treatments exist and multiple ex vivo clinical
candidates. For more information about Precision BioSciences,
please visit www.precisionbiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230605005316/en/
Investor and Media Contact: Mei Burris Director, Investor
Relations and Finance Mei.Burris@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024